J.Safra Asset Management Corp Ascendis Pharma A/S Transaction History
J.Safra Asset Management Corp
- $1.05 Billion
- Q3 2024
A detailed history of J.Safra Asset Management Corp transactions in Ascendis Pharma A/S stock. As of the latest transaction made, J.Safra Asset Management Corp holds 103 shares of ASND stock, worth $14,047. This represents 0.0% of its overall portfolio holdings.
Number of Shares
103
Previous 11
836.36%
Holding current value
$14,047
Previous $1,000
1400.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ASND
# of Institutions
244Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.32 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$700 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$680 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$602 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$571 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.61B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...